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Abstract: Kappa statistics is used for the assessment of agreement
between two or more raters when the measurement scale is categor-
ical. In this short summary, we discuss and interpret the key features
of the kappa statistics, the impact of prevalence on the kappa
statistics, and its utility in clinical research. We also introduce the
weighted kappa when the outcome is ordinal and the intraclass
correlation to assess agreement in an event the data are measured on
a continuous scale.
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(J Thorac Oncol. 2011;6: 6–7)
In most clinical studies, the goal is to assess the associationsbetween the variables of interest. Nevertheless, in the case
of reliability studies, the primary interest is to enumerate the
reproducibility of the same variable. For example, the diag-
nosis of benign versus malignant nodules as rated by two
radiologists or the rating of symptom experiences by patients
with cancer and caregivers. The application of kappa statis-
tics is only appropriate in cases where agreement between the
two raters is of primary interest. If one of the ratings is
considered as a gold standard, then the appropriate measure is
sensitivity and/or specificity.1 In this review, we introduce the
kappa statistic, outline its utility in clinical research, and
discuss the impact of prevalence on the kappa estimates. We
also introduce the weighted kappa statistics when the out-
come is ordinal and the intraclass correlation when data are
measured on a continuous scale.
KAPPA
Dajczman et al.2 compared patient-rated performance
status score with physician-rated Eastern Cooperative Oncol-
ogy Group performance scale among patients with advanced
non-small cell lung cancer (NSCLC). The effect of each
rating on the eligibility of the patient for a hypothetical
clinical trial was assessed. Moderate level of agreement was
reported using the kappa statistic (0.42). Authors also pre-
sented results as percent agreement (0.72). To explain how
these statistics are computed, consider an example where two
radiologists independently review and classify images as
benign or malignant from 100 patients using diagnostic mo-
dalities (x-ray or positron emission tomography [PET] or
computer tomographic [CT] scans) (Table 1).
The observed agreement (P0) between the raters is
given by (30  50)/100  0.80. Nevertheless, this includes
the expected agreement, which is the agreement by chance
alone (Pe) and the agreement beyond chance. Assuming the
rating from the two radiologists is independent of one an-
other, we would have expected (16  36)/100  0.52
agreement by chance alone. This is computed by estimating
the expected frequencies in each cell using a combination of
row and column totals; in this case, the expected number of
malignant nodules called by both readers is 16 (i.e., 40 
40/100), and the expected number of benign nodules called
by both readers is 36 (i.e., 60 60/100). This implies that the
agreement beyond chance would have been P0  Pe, which
is 0.80 0.52 0.38. The maximum value for P0 is 1, which
happens when the ratings from the two radiologists agree on
each of the 100 diagnoses. This implies that the maximum
value for P0  Pe is 1  Pe. Because of the limitation of the
simple proportion of agreement and to keep the maximum
value of the proposed measure to be 1, Cohen3 proposed
kappa as a measure of interrater agreement. It is calculated as
follows: (P0  Pe)/(1  Pe), where (1  Pe) is interpreted as
the proportion of the cases for which the hypothesis of no
association would predict disagreement between the raters.
Kappa values below 0.4 represent poor agreement, values
between 0.4 and 0.75 indicate fair to good agreement, and
values of 0.75 and higher represent excellent agreement.4 In
this example, the kappa statistic would be (0.80 0.52)/(1
0.52) 0.58, which indicates fair to good agreement between
the raters.
IMPACT OF PREVALENCE ON KAPPA
STATISTICS
Kappa statistics is dependent on the prevalence of the
disease. Returning to the example in Table 1, keeping the
proportion of observed agreement at 80%, and changing
the prevalence of malignant cases to 85% instead of 40%
(i.e., higher disease prevalence), the proportion of expected
agreement is 0.745 (Table 2). Thus, the kappa statistics
becomes (0.80  0.745)/(1  0.745)  0.22, instead of 0.58.
Similarly, if the disease prevalence is low, i.e., higher pro-
portion of the cases is benign, the kappa statistics would be
smaller compared with Table 1. Thus, for two studies with the
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same proportion of observed agreement, the maximum value
for the kappa statistics would occur in the study where the
prevalence is closer to 50%. In other words, in extreme cases
where prevalence is very low (e.g., screening population) or
very high (i.e., diagnostic or research studies where sample is
enriched with positive cases), the kappa statistic would be
smaller compared with Table 1. Thus, one needs to exercise
caution while comparing kappa values from different studies.
WEIGHTED KAPPA AND INTRACLASS
CORRELATION
The simple kappa statistics discussed earlier in the text
is relevant to binary ratings. There are several scenarios
where ratings could be given on more than two categories.
For example, consider stage of the disease, which is ordinal,
where the jumps between two consecutive staging levels,
stages 1 to 2 versus stages 2 to 3, are not equal. In this case,
a modified version of the kappa statistics called as the
weighted kappa is calculated allowing one to assign different
weights to the different levels. Weighted kappa is the same as
simple kappa when there are only two ordered categories. A
study by Mac Manus et al.5 prospectively compared the
prognostic value of early posttreatment PET and CT scanning
in a cohort of patients with NSCLC treated with radical
radiotherapy. Agreement between PET and CT was assessed
using weighted kappa, which showed poor agreement be-
tween the two modalities (weighted kappa  0.35).
In certain clinical studies, agreement between the raters
is assessed for a clinical outcome that is measured on a
continuous scale. In such instances, intraclass correlation is
calculated as a measure of agreement between the raters.
Intraclass correlation is equivalent to weighted kappa under
certain conditions, see the study by Fleiss and Cohen6,7 for
details. In a study by Tyng et al.,8 Intraclass correlation (ICC)
was used to compare the gross volume of lung tumors of
patients with NSCLC as defined by specialized radiologist
and radiotherapists of a cancer center. The findings suggested
an excellent agreement between the two (ICC  0.94 and
95% confidence interval: 0.87–98).
SUMMARY
Studies designed to quantify the agreement between the
raters can be analyzed using kappa statistic, weighted kappa,
or intraclass correlation. It is not uncommon to present results
from kappa, weighted kappa, and ICC in a single study when
measurements are taken on a continuous scale. For example,
a study by Guyatt et al.9 reported the reliability of the
assessment of mediastinal lymph node size in CT scan of the
thorax. Authors presented results using each of the three
approaches; kappa, weighted kappa, and ICC. Kappa was
calculated using the node size as enlarged (1 cm) versus not
enlarged (1 cm), weighted kappa was calculated using
creating a variable with four categories (1 cm, 1–1.5 cm,
1.5–2 cm, and 2 cm), and intraclass correlation was calcu-
lated using the actual size measurements. These statistics
provide a useful tool in the quantification of the agreement
between raters.
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TABLE 1. Benign vs. Malignant Ratings of Two
Independent Raters
Rater 2
Rater 1
TotalMalignant Benign
Malignant 30 10 40
Benign 10 50 60
Total 40 60 100
TABLE 2. Benign vs. Malignant Ratings of Two
Independent Raters, When the Disease Prevalence is High
Rater 2
Rater 1
TotalMalignant Benign
Malignant 75 10 85
Benign 10 5 15
Total 85 15 100
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